021-51111890
购物车（）
sales@molnova.cn
3-Phenyltoxoflavin
CAS No. 32502-63-9
3-Phenyltoxoflavin ( ZINC267655 | Phenyltoxoflavin )
产品货号. M28065 CAS No. 32502-63-9
3-Phenyltoxoflavin 是 HSP90 的抑制剂 (Kd = 585 nM)，具有抗癌活性。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥1121 | 有现货 |
|
| 10MG | ￥1891 | 有现货 |
|
| 25MG | ￥3143 | 有现货 |
|
| 50MG | ￥4492 | 有现货 |
|
| 100MG | ￥6057 | 有现货 |
|
| 200MG | ￥8001 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥1292 | 有现货 |
|
生物学信息
-
产品名称3-Phenyltoxoflavin
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述3-Phenyltoxoflavin 是 HSP90 的抑制剂 (Kd = 585 nM)，具有抗癌活性。
-
产品描述3-Phenyltoxoflavin is an inhibitor of HSP90 (Kd = 585 nM) with anti-cancer activity.(In Vitro):3-Phenyltoxoflavin (0.56 nM-100 μM) dose-dependently competes with biotinylated Hsp90 peptide for binding to TPR2A. In BT474 cells, 3-Phenyltoxoflavin (1 nM-100 μM) dose-dependently inhibits cell proliferation with an IC50 of 690 nM.
-
体外实验3-Phenyltoxoflavin (1 nM-100 μM; 4 d) inhibits BT474 cells proliferation in a concentration-dependent manner, with an IC50 of 690 nM.3-Phenyltoxoflavin (0.56 nM-100 μM; 2 h) competes with biotinylated Hsp90 peptide for its binding to TPR2A in a dose-dependent manner.
-
体内实验——
-
同义词ZINC267655 | Phenyltoxoflavin
-
通路Cytoskeleton/Cell Adhesion Molecules
-
靶点HSP
-
受体——
-
研究领域——
-
适应症——
化学信息
-
CAS Number32502-63-9
-
分子量269.26
-
分子式C13H11N5O2
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 7.14 mg/mL (26.52 mM)
-
SMILESO=C1N=C2C(=NC(=NN2C)C3=CC=CC=C3)C(=O)N1C
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Ajeet. QSAR Study of Methionine Aminopeptidase Inhibitors as Anti-cancer Agents Using MLR Approach[J]. american journal of pharmacological sciences. 2013;1(5):80-83, 4 pp.
产品手册
关联产品
-
Alvespimycin
一种有效的口服生物可利用的 Hsp90 抑制剂，结合 EC50 为 62 nM。
-
AMP-PCP
AMP-PCP 是 ATP 类似物，可以结合 Hsp90 N 末端结构域，Kd 值为 3.8 μM。 AMP-PCP 结合有利于 Hsp90 活性同二聚体的形成。
-
PU-H71 HCl
PU-H71 HCl (Zelavespib HCl) is a novel Hsp90 inhibitor, a novel purine-based analog, and a radiosensitizer that may be a promising agent for CIRT. PU-H71 HCL shows antitumor activity in many preclinical models of malignancy. PU-H71 HCL has an inhibitory effect on the protein expression levels of Rad51 and Ku70, which may be associated with the double chain break repair in the homologous recombination pathway and non-homologous end-joining pathway.
